GO:0035726 common myeloid progenitor cell proliferation: Myeloid Expansion Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035726 describes the multiplication of common myeloid progenitor (CMP) cells, the committed myeloid-lineage progenitors that give rise to granulocytes, monocytes, macrophages, dendritic cells, and megakaryocyte-erythroid descendants.
• CMP proliferation is not a passive event; it is instructed by cytokine receptor signaling, transcription-factor networks, and neural inputs that together set the size of the myeloid output.
• Microglia in the adult brain arise from primitive macrophages rather than from adult CMPs, so CMP proliferation must be interpreted within a developmental context.
• Dysregulated CMP proliferation is a hallmark of myeloid malignancies, including NPM1-mutant acute myeloid leukemia and BCOR-altered leukemia, where preleukemic and leukemic clones expand in the progenitor compartment.
• CMPs and their granulocyte-monocyte progenitor (GMP) descendants can be expanded ex vivo and engineered with chimeric antigen receptors, making CMP proliferation a target for cellular immunotherapy manufacturing.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate genes in CMP proliferation, while library screening and bioinformatics resolve the underlying regulatory networks.
Description
GO:0035726, common myeloid progenitor cell proliferation, is the biological process by which common myeloid progenitor (CMP) cells multiply and expand their population. CMPs are progenitor cells committed to the myeloid lineage, and their proliferation is the cellular engine that supplies granulocytes, monocytes, macrophages, and dendritic cells during steady-state hematopoiesis and during emergency myelopoiesis. Because the CMP compartment sits at the branch point between self-renewal and differentiation, the rate at which these cells divide directly determines the size and composition of the mature myeloid pool. For researchers, GO:0035726 is a functional node that connects cytokine receptor signaling, transcription-factor activity, and metabolic state to a measurable output, namely expansion of a defined progenitor population. Cytokine receptor-based chimeric antigen receptors can sequentially control myeloid cell proliferation and differentiation, demonstrating that CMP proliferation is experimentally tunable. Sympathetic neuronal activation triggers myeloid progenitor proliferation and differentiation, showing that the process is also responsive to systemic physiological inputs. In disease, the same proliferative program can be co-opted: NPM1-mutant preleukemia cells and BCOR-altered clones expand within the myeloid progenitor compartment, and therapeutic targeting of these cells depends on understanding how their proliferation is sustained. This article integrates the QuickGO definition of GO:0035726 with verified primary literature to describe what happens during CMP proliferation, which genes and pathways control it, how it is studied with CRISPR and other methods, and why it matters for leukemia, immunotherapy, and myeloid cell biology.
common myeloid progenitor cell proliferation At A Glance
| GO ID | GO:0035726 |
|---|---|
| GO term | common myeloid progenitor cell proliferation |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Definition | The multiplication or reproduction of common myeloid progenitor cells, resulting in the expansion of a cell population; a common myeloid progenitor cell is a progenitor cell committed to the myeloid lineage. |
| Cell type | Common myeloid progenitor (CMP), a committed myeloid-lineage progenitor |
| Major function | Expansion of the CMP pool that supplies granulocyte, monocyte, macrophage, and dendritic cell lineages |
| Upstream inputs | Cytokine receptor signaling and neural/systemic cues |
| Disease relevance | Myeloid leukemia, preleukemia, and myeloid cell-mediated immune regulation |
What Is GO:0035726?
In plain terms, GO:0035726 is the process by which common myeloid progenitor cells make more copies of themselves, expanding the progenitor pool. The QuickGO definition states that it is the multiplication or reproduction of common myeloid progenitor cells, resulting in the expansion of a cell population, where a common myeloid progenitor cell is a progenitor cell committed to the myeloid lineage. This definition places the term at the level of a specific cell type rather than a generic proliferation process, so annotations to GO:0035726 should be supported by evidence that the proliferating cells are CMPs and that the outcome is population expansion.
Why Is common myeloid progenitor cell proliferation Important in Cell Biology?
GO:0035726 matters because the size of the CMP pool sets a ceiling on myeloid output, and perturbations in CMP proliferation propagate into infections, inflammation, and leukemia. Cytokine receptor-based chimeric antigen receptors can sequentially control myeloid cell proliferation and differentiation, which means the process is both a biological checkpoint and an engineering handle. Sympathetic neuronal activation triggers myeloid progenitor proliferation and differentiation, linking the process to neuro-immune communication. In malignancy, NPM1-mutant preleukemia cells and BCOR-altered clones depend on progenitor proliferation for expansion, and targeting these cells requires knowing which proliferative inputs are essential. Finally, myeloid cell-derived arginase in cancer immune response illustrates how the progeny of proliferating CMPs can shape anti-tumor immunity.
• Defines the proliferative step that expands committed myeloid progenitors before differentiation.
• Provides a mechanistic entry point for cytokine receptor signaling in myeloid expansion.
• Connects the nervous system to myeloid progenitor proliferation through sympathetic activation.
• Underlies preleukemic and leukemic clone expansion in NPM1-mutant AML.
• Is dysregulated in BCOR-altered myeloid disease, linking epigenetic regulators to progenitor proliferation.
• Supports ex vivo expansion and CAR engineering of granulocyte-monocyte progenitors for immunotherapy.
• Shapes the abundance of myeloid-derived arginase-expressing cells in the tumor microenvironment.
• Distinguishes adult CMP-derived myelopoiesis from primitive macrophage-derived microglia.
• Offers a measurable phenotype for CRISPR screens and functional genomics in hematopoiesis.
• Informs therapeutic strategies that aim to suppress or harness myeloid progenitor expansion.
What Happens During common myeloid progenitor cell proliferation?
Commitment and identity of the common myeloid progenitor
In simple terms: Before a CMP can divide, it must first be a CMP, meaning a cell already committed to the myeloid lineage.
Common myeloid progenitors are progenitor cells committed to the myeloid lineage and sit downstream of multipotent hematopoietic progenitors. Their identity is defined by lineage commitment rather than by a single marker, and this commitment is what distinguishes GO:0035726 from proliferation of uncommitted stem cells. Fate-mapping studies show that adult microglia derive from primitive macrophages rather than from adult CMPs, which means CMP proliferation must be interpreted within the correct developmental window.
Cytokine receptor-driven proliferative signaling
In simple terms: Cytokines act like keys that unlock proliferation programs in CMPs.
Cytokine receptor signaling is a principal driver of myeloid progenitor proliferation. Sequential control of myeloid cell proliferation and differentiation by cytokine receptor-based chimeric antigen receptors demonstrates that receptor engagement can be engineered to first expand and then differentiate myeloid cells. This indicates that the proliferative phase of GO:0035726 is receptor-instructed and can be separated experimentally from the differentiation phase.
Neural and systemic control of progenitor proliferation
In simple terms: Signals from the nervous system can push myeloid progenitors to divide.
Sympathetic neuronal activation triggers myeloid progenitor proliferation and differentiation, showing that GO:0035726 is not solely a cell-intrinsic process. This neural input links the proliferative expansion of myeloid progenitors to systemic physiological states, and it provides an experimental axis for studying how the nervous system regulates hematopoiesis.
Transcriptional and epigenetic control of expansion
In simple terms: Inside the cell, transcription factors and epigenetic regulators decide whether the progenitor keeps dividing.
BCOR regulates myeloid cell proliferation and differentiation, placing an epigenetic regulator directly on the pathway that controls CMP expansion. In NPM1-mutant acute myeloid leukemia, preleukemia cells expand within the progenitor compartment and can be therapeutically targeted, indicating that transcriptional programs sustaining progenitor proliferation are actionable. Together these findings show that GO:0035726 is controlled by nuclear regulators as well as by external cytokines.
Expansion, differentiation, and downstream myeloid output
In simple terms: Once CMPs have multiplied, their progeny differentiate into the mature myeloid cells that fight infection and shape immunity.
The developmental outcome of CMP proliferation is the production of monocytes, macrophages, and dendritic cells, as reviewed in the framework of monocyte, macrophage, and dendritic cell development. The progeny of expanded myeloid progenitors can also exert immune-regulatory functions, as illustrated by myeloid cell-derived arginase in cancer immune response. Expansion and CAR engineering of granulocyte-monocyte progenitors further shows that the proliferative output of this compartment can be redirected for cellular immunotherapy.
Key Genes Involved in GO:0035726 common myeloid progenitor cell proliferation
The following genes and proteins have been experimentally linked to common myeloid progenitor proliferation, myeloid progenitor expansion, or the differentiation programs that follow it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NPM1 | Nuclear regulator whose mutation sustains preleukemic progenitor expansion | Therapeutic targeting of preleukemia cells in NPM1-mutant AML |
| BCOR | Epigenetic regulator of myeloid cell proliferation and differentiation | Links epigenetic control to progenitor expansion in leukemia |
| CSF2RB | Cytokine receptor subunit used in chimeric antigen receptors to control myeloid proliferation | Sequential control of proliferation and differentiation |
| CSF2RA | Cytokine receptor subunit partnering with CSF2RB in myeloid signaling | Cytokine receptor-based control of myeloid cells |
| KIT | Receptor tyrosine kinase expressed on myeloid progenitors | Myeloid progenitor proliferation and differentiation |
| MPO | Myeloid granule protein marking committed myeloid progenitors | CMP identity and myeloid lineage commitment |
| LYZ | Myeloid enzyme marking monocyte/macrophage progeny | Downstream output of CMP proliferation |
| ITGAM | Myeloid integrin marking monocyte/macrophage lineages | Myeloid differentiation after progenitor expansion |
| SPI1 | Myeloid transcription factor controlling progenitor programs | Myeloid lineage commitment and proliferation |
| CEBPA | Transcription factor controlling granulocyte-monocyte differentiation | Balance between CMP proliferation and differentiation |
| GATA2 | Transcription factor in myeloid progenitor regulation | Progenitor identity and expansion |
| RUNX1 | Transcription factor in hematopoietic progenitor regulation | Myeloid progenitor biology and leukemia |
| FLT3 | Receptor tyrosine kinase on myeloid progenitors | Progenitor proliferation signaling |
| ARG1 | Myeloid-derived arginase shaping immune response | Immune consequences of myeloid expansion |
| P2RY12 | Microglial marker distinguishing primitive macrophage-derived cells | Contrasts adult microglia with CMP-derived myeloid cells |
| CX3CR1 | Myeloid chemokine receptor in monocyte/macrophage biology | Myeloid progeny tracking after progenitor expansion |
| CSF1R | Receptor controlling monocyte/macrophage development | Downstream myeloid differentiation |
How Is common myeloid progenitor cell proliferation Regulated?
GO:0035726 is regulated at multiple levels. Cytokine receptor signaling provides an external proliferative input, and cytokine receptor-based chimeric antigen receptors can sequentially control myeloid cell proliferation and differentiation, showing that receptor engagement is a tunable regulatory node. Neural inputs also regulate the process, because sympathetic neuronal activation triggers myeloid progenitor proliferation and differentiation. Intracellularly, BCOR regulates myeloid cell proliferation and differentiation, indicating epigenetic control of the proliferative program. In NPM1-mutant acute myeloid leukemia, preleukemia cells expand in the progenitor compartment and can be therapeutically targeted, which implies that the regulatory circuitry sustaining proliferation is druggable. Together, these layers define a regulatory network in which external cytokines, systemic neural signals, and nuclear regulators converge on CMP expansion.
common myeloid progenitor cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPM1 | NPM1-mutant acute myeloid leukemia and preleukemia | Knock-in of mutant NPM1 in myeloid progenitor lines or primary cells |
| BCOR | Myeloid leukemia and altered myeloid proliferation/differentiation | CRISPR knockout of BCOR in myeloid progenitor models |
| CSF2RB | Engineered control of myeloid proliferation for immunotherapy | Knock-in of cytokine receptor-based chimeric antigen receptors |
| ARG1 | Myeloid-derived immune suppression in cancer | Overexpression or knockout in myeloid cell models |
| KIT | Myeloid progenitor proliferation signaling | Point-mutation and knockout models in progenitor cells |
Acute myeloid leukemia and preleukemia
Dysregulated common myeloid progenitor proliferation is central to myeloid malignancy. In a mouse model of NPM1-mutant acute myeloid leukemia, preleukemia cells expand within the progenitor compartment and can be therapeutically targeted, demonstrating that the proliferative program of committed myeloid progenitors is a disease-sustaining process. BCOR regulates myeloid cell proliferation and differentiation, and its alteration is linked to myeloid disease, reinforcing the idea that epigenetic regulators of GO:0035726 contribute to leukemia.
Myeloid cells in cancer immune response
The progeny of proliferating CMPs can shape anti-tumor immunity. Myeloid cell-derived arginase in cancer immune response illustrates how expanded myeloid populations can suppress immune effector function, linking GO:0035726 to the immunosuppressive tumor microenvironment. This connection makes CMP proliferation a potential indirect target in immuno-oncology, because limiting the expansion of arginase-expressing myeloid cells could relieve immune suppression.
Neuro-immune and developmental contexts
Sympathetic neuronal activation triggers myeloid progenitor proliferation and differentiation, indicating that neural signals can drive GO:0035726 in vivo. In the brain, fate-mapping analysis reveals that adult microglia derive from primitive macrophages rather than from adult CMPs, which is essential for correctly attributing myeloid cell origins in neurobiology studies. These findings show that CMP proliferation must be interpreted alongside developmental origin and systemic physiology.
Cellular immunotherapy manufacturing
Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy demonstrates that controlled proliferation of myeloid progenitors can be harnessed therapeutically. Because cytokine receptor-based chimeric antigen receptors can sequentially control myeloid cell proliferation and differentiation, the proliferative step of GO:0035726 is directly relevant to manufacturing engineered myeloid cell products.
From common myeloid progenitor cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for CMP proliferation? | CRISPR knockout in myeloid progenitor cell lines or primary CMPs |
| Does a specific mutation drive progenitor expansion? | Point-mutation knock-in of the variant of interest |
| Can a signaling receptor be rewired to control proliferation? | Knock-in of chimeric antigen receptor constructs |
| Where and when is a candidate protein expressed during expansion? | Tagged knock-in with a fluorescent or epitope tag |
| Does overexpression of a gene expand the CMP pool? | Overexpression of the candidate gene in progenitor models |
| Which genes are required for CMP proliferation at scale? | CRISPR library screening in myeloid progenitor systems |
How to Study the common myeloid progenitor cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Frequency and phenotype of CMPs and progeny | Quantifying progenitor expansion and differentiation |
| Cytokine receptor-based proliferation assay | Proliferative response to engineered receptor signaling | Separating proliferation from differentiation |
| In vivo neural activation models | Systemic control of myeloid progenitor proliferation | Testing neuro-immune regulation of GO:0035726 |
| Leukemia mouse models | Expansion and targeting of preleukemic progenitors | Evaluating therapeutic strategies |
| Epigenetic regulator perturbation | Effect of BCOR and related factors on proliferation | Linking chromatin regulation to progenitor expansion |
| CAR engineering of progenitors | Expansion and function of engineered myeloid cells | Immunotherapy manufacturing |
| Myeloid-derived arginase assays | Immune-regulatory output of expanded myeloid cells | Cancer immune response studies |
| Fate-mapping analysis | Developmental origin of myeloid populations | Distinguishing CMP-derived cells from primitive macrophages |
Flow cytometry and progenitor phenotyping
Flow cytometry is the standard method for identifying common myeloid progenitors and measuring their expansion. Because CMPs are defined by lineage commitment and surface phenotype, flow-based enumeration of progenitor populations is required to attribute a proliferation phenotype to GO:0035726 rather than to a generic myeloid expansion. This approach is also used to track differentiation of expanded progenitors into monocytes, macrophages, and dendritic cells.
Cytokine and receptor-based proliferation assays
Cytokine receptor-based chimeric antigen receptors can sequentially control myeloid cell proliferation and differentiation, providing an assay format in which receptor engagement is manipulated and proliferative output is measured. Such assays allow researchers to separate the proliferation phase from the differentiation phase and to test whether a candidate gene acts in the proliferative step of GO:0035726.
In vivo neural and systemic perturbation
Sympathetic neuronal activation triggers myeloid progenitor proliferation and differentiation, so in vivo models that manipulate neural inputs can be used to study systemic regulation of GO:0035726. These experiments link the progenitor compartment to physiological state and complement cell-intrinsic assays.
Disease-model and therapeutic targeting studies
Mouse models of NPM1-mutant acute myeloid leukemia allow researchers to test whether therapeutic targeting of preleukemia cells affects progenitor proliferation. Similarly, BCOR studies connect epigenetic regulators to myeloid proliferation and differentiation, and expansion and CAR engineering of granulocyte-monocyte progenitors provides a translational readout for controlled proliferation.
How CRISPR Can Be Used to Study GO:0035726 common myeloid progenitor cell proliferation
Knockout
CRISPR knockout is used to test whether a candidate gene is required for common myeloid progenitor proliferation. For example, knocking out BCOR in myeloid progenitor models can reveal its role in proliferation and differentiation, directly informing GO:0035726. Knockout of genes such as NPM1-pathway components or cytokine receptor subunits can similarly define essential proliferative inputs.
Point Mutation
Point-mutation knock-in allows researchers to model disease-associated variants in myeloid progenitors. NPM1-mutant acute myeloid leukemia models depend on expressing the mutant protein in the appropriate progenitor context, and CRISPR point-mutation approaches can recreate such alleles to test their effect on progenitor expansion. This is essential when the question is not whether a gene is present but whether a specific variant drives proliferation.
Knock-in
Knock-in strategies are used to introduce reporters, tags, or engineered receptors into myeloid progenitors. Cytokine receptor-based chimeric antigen receptors can be knocked in to sequentially control myeloid cell proliferation and differentiation, providing a precise way to manipulate GO:0035726. Tagged knock-in of progenitor markers also supports tracking of CMP identity and progeny.
Overexpression
Overexpression models test sufficiency, that is, whether increasing a gene's activity expands the CMP pool. Overexpression of immune-regulatory genes such as ARG1 in myeloid cells can be used to study the downstream consequences of myeloid expansion in cancer immune response. Overexpression complements knockout by revealing gain-of-function effects on GO:0035726.
How EDITGENE Supports common myeloid progenitor cell proliferation Research
Researchers studying common myeloid progenitor cell proliferation-related genes often need to determine whether a candidate gene is causally involved in progenitor expansion or is merely correlated with it. Establishing causality requires controlled genetic perturbation in relevant myeloid progenitor models, followed by functional readouts of proliferation and differentiation.
Contact EDITGENE today to design your custom CRISPR model for common myeloid progenitor cell proliferation research.
Frequently Asked Questions About common myeloid progenitor cell proliferation
What is GO:0035726 common myeloid progenitor cell proliferation?
GO:0035726 is the biological process in which common myeloid progenitor cells multiply and expand their population; a common myeloid progenitor is a progenitor cell committed to the myeloid lineage.
What genes are involved in common myeloid progenitor cell proliferation?
Genes experimentally linked to this process include NPM1, BCOR, cytokine receptor subunits such as CSF2RB, and signaling receptors such as KIT, based on studies of myeloid progenitor expansion and differentiation.
Why is common myeloid progenitor proliferation important in leukemia?
In NPM1-mutant acute myeloid leukemia, preleukemia cells expand in the progenitor compartment and can be therapeutically targeted, showing that progenitor proliferation sustains disease. BCOR also regulates myeloid cell proliferation and differentiation, linking epigenetic control to myeloid disease.
How do cytokines control common myeloid progenitor proliferation?
Cytokine receptor signaling drives myeloid progenitor proliferation, and cytokine receptor-based chimeric antigen receptors can sequentially control proliferation and differentiation, demonstrating that receptor engagement is a tunable control point.
Does the nervous system affect myeloid progenitor proliferation?
Yes. Sympathetic neuronal activation triggers myeloid progenitor proliferation and differentiation, indicating that neural signals can regulate this process in vivo.
Do adult microglia come from common myeloid progenitors?
No. Fate-mapping analysis shows that adult microglia derive from primitive macrophages rather than from adult common myeloid progenitors, so CMP proliferation must be interpreted within the correct developmental context.
How can CRISPR be used to study common myeloid progenitor proliferation?
CRISPR knockout can test requirement, point-mutation knock-in can model disease alleles such as NPM1 mutations, knock-in can introduce engineered receptors, and overexpression can test sufficiency for progenitor expansion.
What methods measure common myeloid progenitor proliferation?
Flow cytometry quantifies progenitor populations, cytokine receptor-based assays measure proliferative responses, in vivo neural activation models test systemic control, and leukemia models test therapeutic targeting.
What is the role of myeloid-derived arginase in cancer?
Myeloid cell-derived arginase contributes to cancer immune response, illustrating how the progeny of expanded myeloid progenitors can suppress anti-tumor immunity.
Can common myeloid progenitors be used for immunotherapy?
Yes. Expansion and CAR engineering of granulocyte-monocyte progenitors has been developed for cellular immunotherapy, showing that controlled progenitor proliferation can be harnessed therapeutically.
Conclusion
GO:0035726, common myeloid progenitor cell proliferation, defines the expansion of committed myeloid progenitors that supply granulocytes, monocytes, macrophages, and dendritic cells. The process is instructed by cytokine receptor signaling, modulated by neural inputs, and controlled intracellularly by transcriptional and epigenetic regulators such as BCOR and NPM1. Because the same proliferative program can be co-opted in leukemia and can be harnessed for cellular immunotherapy, it is a high-value target for functional genomics. Researchers can interrogate GO:0035726 with CRISPR knockout, point-mutation, knock-in, and overexpression models, combined with flow cytometry, cytokine assays, and in vivo perturbation. Library screening and bioinformatics further extend these approaches to discover and prioritize novel regulators of myeloid progenitor expansion.
References
- 1. Ginhoux F et al.. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages.. Science 330(6005):841-5 PMID: 20966214
- 2. Geissmann F et al.. 2010. Development of monocytes, macrophages, and dendritic cells.. Science 327(5966):656-61 PMID: 20133564
- 3. Yue S et al.. 2026. Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy.. Cell 189(17):5378-5395.e11 PMID: 42320470
- 4. Uckelmann HJ et al.. 2020. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia.. Science 367(6477):586-590 PMID: 32001657
- 5. Nakajima K et al.. 2022. Sequential control of myeloid cell proliferation and differentiation by cytokine receptor-based chimeric antigen receptors.. PLoS One 17(12):e0279409 PMID: 36574389
- 6. Vasamsetti SB et al.. 2018. Sympathetic Neuronal Activation Triggers Myeloid Progenitor Proliferation and Differentiation.. Immunity 49(1):93-106.e7 PMID: 29958804
- 7. Cao Q et al.. 2016. BCOR regulates myeloid cell proliferation and differentiation.. Leukemia 30(5):1155-65 PMID: 26847029
- 8. Grzywa TM et al.. 2020. Myeloid Cell-Derived Arginase in Cancer Immune Response.. Front Immunol 11:938 PMID: 32499785
